13 Pharmas Sign Roadmap For Antibiotic Reform – But What Do They Want?
Executive Summary
More than 13 global pharma companies, including GlaxoSmithKline, Pfizer and Merck & Co., have agreed a "Roadmap" aimed at relieving the growing antimicrobial resistance crisis worldwide – as well as principles to explore alternative business models and incentives for antibiotic R&D and reimbursement.
You may also be interested in...
Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal
Evotec's CEO tells Scrip its pact with Sanofi to develop an infectious disease pipeline could offer a commercially viable approach to battling the global AMR crisis.
O'Neill Warns Pharma Risks Backlash If Doesn't Engage In World AMR Pact
The globalized drugs industry needs to play ball and help find a solution to antimicrobial resistance or risk getting blamed for its failure and the resulting world health crisis.
Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government
Having suddenly resigned from the UK government, Jim O’Neill says he’s now available to take on a global role, if asked, to promote concrete action on tackling antimicrobial resistance within promised timeframes.